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Abstract
The tissue distribution of indinavir, free or incorporated into sterically stabilized anti-HLA-DR immunoliposomes, has
been evaluated after a single subcutaneous injection to C3H mice. Administration of free indinavir resulted in low drug levels
in lymphoid organs. In contrast, sterically stabilized anti-HLA-DR immunoliposomes were very efficient in delivering high
concentrations of indinavir to lymphoid tissues for at least 15 days post-injection increasing by up to 126 times the drug
accumulation in lymph nodes. The efficacy of free and immunoliposomal indinavir has been evaluated in vitro. Results
showed that immunoliposomal indinavir was as efficient as the free agent to inhibit HIV-1 replication in cultured cells. The
toxicity and immunogenicity of repeated administrations of liposomal formulations have also been investigated in rodents.
No significant differences in the levels of hepatic enzymes of mice treated with free or liposomal indinavir were observed
when compared to baseline and control untreated mice. Furthermore, histopathological studies revealed no significant
damage to liver and spleen when compared to the control group. Liposomes bearing FabP fragments were 2.3-fold less
immunogenic than liposomes bearing the entire IgG. Incorporation of antiviral agents into sterically stabilized
immunoliposomes could represent a novel therapeutic strategy to target specifically HIV reservoirs and treat more
efficiently this retroviral infection. ß 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Human immunode¢ciency virus (HIV) primary in-
fection is characterized by an early burst of viremia
followed by an HIV-speci¢c immune response which
results in a dramatic decline of virus in plasma. This
initial period of infection is consistent with the dis-
semination of viral particles throughout the whole
body, and more particularly in lymphoid organs
[1]. The high viral load observed in the lymphoid
tissues was reported to be associated with trapped
HIV particles on the follicular dendritic cells (FDC)
located in the germinal centers [2^7]. Furthermore,
the viral replication in lymph nodes was shown to be
generally 10^100-fold higher than that in peripheral
blood mononuclear cells [6]. Considering that HIV
accumulates and replicates actively within lymphoid
tissues, any strategy that will decrease viral stores in
these tissues might be bene¢cial to the infected host.
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Highly active antiretroviral therapy (HAART) has
been shown to be e¡ective in reducing the plasma
viral load in HIV-infected individuals and to elimi-
nate about 90% of viral particles in lymphoid organs
[8,9]. However, replication-competent HIV-1 has
been isolated from lymphoid organs of patients
even after 30 months of therapy [10^16]. Moreover,
the initiation of HAART as early as 10 days after the
onset of symptoms of primary infection could not
prevent the establishment of a pool of latently in-
fected resting CD4 T cells [17]. It was estimated
that 60 years of therapy would be required before
complete eradication of the virus assuming a half-
life of replication-competent HIV in the latently in-
fected resting CD4 T cells of about 44 months [18].
An increasing number of treatment failures resulting
from toxicity, drug-resistant mutants and poor com-
pliance of patients with the drug regimen are also
emerging with long-term therapy. Thus, there is a
need to develop strategies aimed at reducing persis-
tent viral replication in lymphoid tissues and prevent-
ing new viral dissemination by reactivation of in-
fected resting CD4 T cells.
Liposome-based therapy represents a logical ap-
proach to improve the delivery of anti-HIV agents
into lymphoid tissues to prevent establishment of an
HIV reservoir as well as viral replication during the
clinical latency period. Our previous observations
showed that liposomes allow high intracellular pene-
tration of drugs, good in vitro antiviral e⁄cacy
against HIV-1, e⁄cient targeting of macrophage-
rich tissues and a marked improvement of the phar-
macokinetics of drugs [19^26]. On the other hand,
the coupling of poly(ethyleneglycol) (PEG) on the
surface of liposomes (sterically stabilized liposomes)
was shown to decrease their rate of uptake by the
mononuclear phagocytic system allowing liposomes
to accumulate to higher levels in lymph nodes and
reducing their accumulation at the subcutaneous site
of injection [27,28]. As protease inhibitors possess
low bioavailability, poor intracellular accumulation
and high binding to plasma proteins, their incorpo-
ration into sterically stabilized liposomes will, most
likely, positively a¡ect their biodistribution. Recent
studies have shown that sterically stabilized lipo-
somes containing a protease inhibitor were as e⁄-
cient as the free drug to inhibit HIV replication in
macrophages [29,30].
FDC, B lymphocytes, antigen-presenting cells like
macrophages and activated CD4 T cells are abun-
dant in lymphoid tissues and all express substantial
levels of the HLA-DR determinant of the major his-
tocompatibility complex class II molecules. Mono-
cyte-derived macrophages, which are also CD4
and express HLA-DR, are the most frequently iden-
ti¢ed hosts of HIV-1 in tissues of infected individuals
[31,32]. Our previous studies showed that the subcu-
taneous injection of liposomes bearing anti-HLA-DR
FabP fragments to mice resulted in an increased ac-
cumulation in lymph nodes when compared to non-
targeted liposomes [33]. Moreover, sterically stabi-
lized anti-HLA-DR immunoliposomes accumulated
much better than conventional immunoliposomes in
lymphoid tissues indicating that the presence of PEG
has an important e¡ect on the uptake of immunoli-
posomes by the lymphatic system [34]. In the present
study, the tissue distribution and in vitro e⁄cacy of
free and immunoliposomal indinavir were evaluated.
The toxicity and immunogenicity of repeated admin-
istrations of liposomal formulations have also been
investigated in rodents.
2. Materials and methods
2.1. Chemicals
Dipalmitoylphosphatidylcholine (DPPC) and di-
palmitoylphosphatidylglycerol (DPPG) were pur-
chased from Avanti Polar Lipids (Alabaster, AL,
USA). Distearoylphosphatidylethanolamine^[poly-
(ethyleneglycol) 2000]^maleimide (DSPE^PEG^MAL)
was purchased from Shearwater Polymers Inc.
(Hunstville, AL, USA). [3H]Indinavir and L-3-phos-
phatidylcholine,1,2-di[1-14C]palmitoyl (14C-DPPC)
were purchased from Moravek Biochemicals (Brea,
CA, USA) and Amersham Life Science (Baie-d’Urfe¤,
QC, Canada), respectively. Lysyl endopeptidase ob-
tained from Achromobacter lyticus was purchased
from Wako Chemicals (Richmond, VA, USA).
2.2. Cells
Sup-T1, a human CD4 T lymphocyte cell line,
PM1, a clonal derivative of HUT 78 cells, and
RAJI, an Epstein^Barr virus-carrying B cell line
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that express high levels of cell surface HLA-DR, -DP
and -DQ proteins were obtained from the American
Type Culture Collection (ATCC, Rockville, MD).
RAJI-CD4 cells were obtained by transfection of
RAJI cells with a CD4-expressing vector. All cells
were maintained in RPMI 1640 supplemented with
10% fetal bovine serum (FBS), 2 mM L-glutamine,
100 U/ml penicillin G and 100 Wg/ml streptomycin
(Gibco-BRL, Burlington, ON, Canada).
2.3. Monoclonal antibodies
Hybridomas producing monoclonal antibodies di-
rected against murine HLA-DR (clone Y-17, IgG2b),
human HLA-DR (clone 2.06, IgG1) and human CD4
(clone OKT4, IgG2b) were grown in RPMI 1640 sup-
plemented with 10% FBS, 2 mM L-glutamine, 100
U/ml penicillin G and 100 Wg/ml streptomycin. Cells
were then cultivated in BALB/c mice (18^20 g;
Charles River Laboratories, St-Constant, QC, Cana-
da) and antibodies were isolated from ascites £uids.
Antibodies were puri¢ed using a protein G a⁄nity
column (Pharmacia, Baie d’Urfe¤, QC, Canada), steri-
lized on 0.22 Wm low binding protein ¢lters and
stored at 320‡C in phosphate-bu¡ered saline (PBS,
pH 7.4) until use. Purity of antibodies was assessed
by sodium dodecyl sulfate polyacrylamide gel elec-
trophoresis (SDS^PAGE) under non-reducing condi-
tions. The apparent molecular weight was veri¢ed
using BenchMarker prestained protein ladder (Gib-
co-BRL, Grand Island, NY, USA). Gel staining was
performed with Coomassie brilliant blue (Sigma, St.
Louis, MO, USA). The immunoreactivity of Y-17,
2.06 and OKT4 antibodies was tested by £ow cyto-
metry on freshly prepared C3H mouse spleen cells,
RAJI-CD4 cells and Sup-T1 cells, respectively. In
brief, suspension of cells (106 cells/ml) was incubated
with 7 Wg of 2.06 or with 1 Wg of OKT4 or biotinyl-
ated Y-17 for 30 min at 4‡C. Cells were washed with
PBS and incubated for 30 min at 4‡C with 1 Wg
R-phycoerythrin-conjugated streptavidin (Jackson
ImmunoResearch Laboratories, West Grove, PA,
USA) for Y-17, 1 Wg of R-phycoerythrin-conjugated
goat anti-mouse (Southern Biotechnology Associates,
Birmingham, AL, USA) for 2.06 and with 1:50 £uo-
rescein isothiocyanate-conjugated goat anti-mouse
IgG (Cederlane Laboratories, Hornby, ON, Canada)
for OKT4. Cells were then washed three times with
PBS. RAJI-CD4 cells were ¢xed in 2% paraformal-
dehyde and all cells were kept on ice under darkness
until assessment of £uorescence by £ow cytometry
(Coulter Electronics, Miami, FL, USA). Irrelevant
isotype-matching antibodies were used as control.
In agreement with our previous published data, re-
sults showed a very strong binding of immunolipo-
somes for these cell lines (data not shown) [33].
2.4. Preparation of FabP fragments
F(abP)2 fragments of OKT4 and Y-17 antibodies
were produced following incubation of the antibodies
with lysyl endopeptidase (in 50 mM Tris^HCl, pH
8.5) in an enzyme/substrate molar ratio of 1:50 for
3 h at 37‡C. Lysyl endopeptidase cleaved IgG2b at Lys
228E/Cys 229 without perturbing disul¢de bridges
[35]. The enzyme was removed by gel chromatogra-
phy on a Sephadex G-25M column whereas undi-
gested IgG and Fc fragments were removed using a
protein A a⁄nity chromatography column. F(abP)2
fragments were resuspended in a phosphate^EDTA
bu¡er (100 mM sodium phosphate and 5 mM
EDTA, pH 6.0). F(abP)2 fragments of antibody
2.06 were produced using an Immunopure IgG1
FabP and F(abP)2 preparation kit (Pierce, Rockford,
IL, USA) as previously described by us [33]. FabP
fragments were obtained by reduction of F(abP)2
fragments with 6 mg of 2-mercaptoethylamine^HCl
in phosphate^EDTA bu¡er for 90 min at 37‡C. The
solution was eluted on a Sephadex G-25M column
pre-equilibrated with PBS and fractions containing
FabP fragments were concentrated on Centricon-10
(Amicon, Beverly, MA, USA) and kept under a ni-
trogen atmosphere at 4‡C until coupling to lipo-
somes. Purity of FabP fragments was assessed by
SDS^PAGE analysis.
2.5. Preparation of immunoliposomes containing
indinavir
Sterically stabilized liposomes composed of DPPC/
DPPG/DSPE^PEG^MAL (10:3:0.83 mol/mol) were
prepared by hydrating a dried lipid ¢lm with a solu-
tion of indinavir. This solution was prepared by ¢rst
solubilizing indinavir in dimethylsulfoxide (DMSO)
at a concentration of 160 mg/ml followed by the
addition of PBS to reach a ¢nal drug concentration
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of 25 mM. A small proportion of [14C]DPPC and
[3H]indinavir was added as radioactive tracers. Mul-
tilamellar vesicles were extruded through 0.1 Wm po-
lycarbonate membrane. Unencapsulated drug was re-
moved by centrifugation (275Ug for 15 min at 4‡C)
of the liposomal preparation through a Sephadex G-
50 column and e⁄ciency of drug entrapment was
determined by radioactive counting. The mean
vesicle size of the liposomes, as evaluated with a
submicron particle analyzer (Coulter Electronics, Hi-
aleah, FL, USA), was between 100 and 120 nm. For
the coupling procedure, sterically stabilized lipo-
somes were incubated with freshly prepared FabP
fragments (35 Wg FabP fragments/Wmol lipid) over-
night at 4‡C under agitation and under a nitrogen
atmosphere. Uncoupled FabP fragments were re-
moved through a Sepharose CL-4B size exclusion
column (Sigma, St. Louis, MO, USA) and the total
amount of FabP conjugated to liposomes (5^15 Wg/
Wmol of lipids) was evaluated using a Coomassie
protein assay reagent (Pierce, Rockford, IL, USA).
2.6. Tissue and plasma distribution
A single bolus of free or immunoliposomal indina-
vir (1.1 mg indinavir/kg; 0.6 WCi of [3H]indinavir;
0.2 WCi of [14C]DPPC) was injected below the neck
of female C3H mice (18^20 g; Charles River Labo-
ratories, St-Constant, QC, Canada) in a volume of
500 Wl. At speci¢c time points post-injection, animals
were killed and blood was collected and separated by
centrifugation (2800Ug for 10 min at 4‡C) and se-
lected tissues (liver, spleen, cervical, brachial, ingui-
nal, mesenteric and popliteal lymph nodes) were col-
lected, washed in PBS and weighed. All samples were
treated with tissue solubilizer (Beckman Instruments,
Fullerton, CA, USA) and drug and lipid levels were
determined from radioactivity counts.
2.7. In vitro e⁄cacy experiments
The ability of indinavir, free and encapsulated in
liposomes or anti-HLA-DR and anti-CD4 immuno-
liposomes, to inhibit HIV-1 replication was moni-
tored in PM1 and Sup-T1 cells, respectively. Brie£y,
1.25U105 cells were incubated with HIV-1 (strain
NL4-3; 10 ng of p24) and di¡erent concentrations
of free or liposomal indinavir (10^100 nM) in a ¢nal
volume of 500 Wl. Cells were maintained in RPMI
1640 supplemented with 10% FBS, 2 mM L-gluta-
mine, 100 U/ml penicillin G and 100 Wg/ml strepto-
mycin. Twice a week, 50 Wl of supernatant was col-
lected and stored at 320‡C until assayed for reverse
transcriptase activity and 200 Wl of cell suspension
was removed for cell viability assays. Thereafter,
250 Wl of fresh culture medium was added in each
well. Reverse transcriptase activity was measured by
incubating supernatant with 10 Wl of solution A (5
mM dithiothreitol, 50 mM KCl, 0.05% Triton X-100)
and 40 Wl of solution B (5 mM MgCl2, 0.5 M EGTA,
0.04 mg of poly(rA)-oligo(dT)12ÿ18, 3 mCi [3H]TTP
(40^70 Ci/mmol)). After a 1 h incubation period at
37‡C, samples were precipitated onto glass ¢ber ¢l-
ters by using a cell harvester system and reverse tran-
scriptase activity was measured using a liquid scintil-
lation counter (1205 Beta-plate; Wallac Oy, Turku,
Finland). Solutions of DMSO at the same concen-
trations as used for the preparation of the indinavir
solutions were used as controls. The cell viability was
determined using a tetrazolium salt in the presence of
a phenazine methosulfate-based colorimetric assay as
previously described [36].
2.8. In vivo toxicity
Female C3H mice (18^20 g) (group of 10 mice)
were injected subcutaneously with 500 Wl of indina-
vir, free or incorporated in sterically stabilized lipo-
somes (34.3 mg indinavir/kg; 540 mg of lipids/kg
body weight/day), once daily for 10 days and allowed
to recover for 14 days. The choice of this dose was
based on daily doses administered to HIV-infected
patients. Animals treated with PBS and with a
0.86% DMSO solution were used as controls. Blood
samples were collected on days 0, 11 and 24 for bio-
chemical analysis. Levels of aspartate aminotransfer-
ase, alanine aminotransferase and lactate dehydroge-
nase were monitored in serum samples in the clinical
biochemistry laboratory of the CHUL. On days 11
and 24, ¢ve mice/group were killed and histopatho-
logical studies were performed on liver and spleen.
In brief, tissues were ¢xed in a solution of 10%
formalin for 4 days. After ¢xation, tissues were
dehydrated and embedded in para⁄n. Sections
(5 Wm thick) were placed on gelatin-coated slides
and allowed to dry for 4 h at 37‡C. Slides were
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depara⁄nized in toluene and hydrated in a series
of graded ethanol solutions. During hydration, resid-
ual formalin was neutralized in ethanol-saturated
picric acid. Slides were stained with hematoxylin^
eosin and tissues were dehydrated, cleared and
mounted with Permount (Fisher Scienti¢c, Montre¤al,
QC, Canada).
2.9. Immunogenicity of immunoliposomes
Adult male Sprague^Dawley rats (200^250 g) were
injected subcutaneously on days 0, 7, 14 and 21 with
3 Wmol of sterically stabilized liposomes bearing anti-
HLA-DR FabP fragments or parent IgG (2U10310
mol protein/Wmol lipid), liposomes alone or a mix-
Fig. 1. Tissue and plasma distribution of free indinavir and of sterically stabilized anti-HLA-DR immunoliposomes containing indina-
vir as a function of time after a single bolus subcutaneous administration given in the upper back below the neck of C3H mice. Val-
ues represent the means ( þ S.E.M.) obtained from six animals per group per time point.
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ture of liposomes and FabP fragments or complete
IgG. Blood samples were collected at di¡erent time
points (days 0, 6, 13, 20 and 27) and antibody titers
in serum samples were quanti¢ed by sandwich ELI-
SA using Nunc MaxiSorp microtiters plates (Nunc
Brand Products, Naperville, IL, USA). In brief,
plates were coated with 5 Wg/ml (100 Wl/well) of the
tested proteins (FabP fragments, whole IgG or irrel-
evant protein, BSA) for 2 h at 37‡C. Afterwards,
plates were washed three times with PBS containing
0.2% Tween 20 and incubated with blocking bu¡er
(PBS+5% BSA) for 30 min at 37‡C. Plates were
washed and serum dilutions from immunized animals
were added (100 Wl/well), incubated for 1 h at 37‡C
and washed again to remove unbound proteins. A
biotin-conjugated goat anti-rat IgG (ICN Biomedi-
cals, Costa Mesa, CA, USA) solution (100 Wl/well,
diluted 1:50 000 in blocking bu¡er) was added to
each well and plates were incubated for 1 h at
room temperature. Unbound antibodies were washed
with PBS containing 0.2% Tween 20 and horseradish
peroxidase-conjugated streptavidin (100 Wl/well, di-
luted 1:4000 in PBS containing 2% BSA and 0.05%
Tween 20) was added and incubated for 30 min at
room temperature. After three washes, hydrogen per-
oxide 3,3P,5,5P-tetramethylbenzidine (100 Wl/well) was
added to the solution and after a 30 min incubation
at room temperature, the reaction was stopped by
adding 50 Wl of a 1 M H3PO4 solution. Absorbance
was read at 450 nm on a microplate reader.
2.10. Statistical analysis
Statistical analyses were performed using a com-
puter package (Statview+SE Software, Abacus Con-
cepts, Berkeley, CA, USA). Signi¢cance between
groups was statistically evaluated using a one-way
analysis of variance (ANOVA) test, followed by
t-test with FisherPs corrections.
3. Results
3.1. Characterization of liposomal indinavir
The encapsulation e⁄ciency of indinavir in immu-
noliposomes having a mean vesicle diameter ranging
between 100 and 120 nm was 11 þ 4%. No drug re-
lease was observed when the liposomal formulation
was stored for 3 months at 4‡C in PBS. About 75%
of the drug was released after a 24 h incubation in
PBS and 90% FBS at 37‡C. However, after this ini-
tial drug release, complete retention of drugs in lipo-
somes was observed for at least 14 days (data not
shown). Evaluation of the liposome diameter showed
no liposome aggregation over time.
3.2. Tissue and plasma distribution
Fig. 1 shows the tissue distribution of indinavir,
free or incorporated into sterically stabilized anti-
HLA-DR immunoliposomes, after a single bolus
subcutaneous administration given in the upper
back neck of C3H mice. Administration of free in-
dinavir resulted in very low drug levels in all lym-
phoid tissues (panel A). Most of the injected drug
accumulated in the liver and was totally cleared with-
in 24 h post-administration. In contrast, the incorpo-
ration of indinavir in immunoliposomes markedly
improved the tissue and plasma distribution. Steri-
Table 1
Area under the curve for free and immunoliposomal indinavir in tissues after a single subcutaneous administration in mice
Tissue Immunoliposomal indinavir Free indinavir Ratio immunoliposomal/free indinavir
Cervical lymph nodes 523.2 7.6 68.8
Brachial lymph nodes 617 4.9 126.0
Mesenteric lymph nodes 192.8 6.4 30.1
Inguinal lymph nodes 144.5 4.1 35.2
Popliteal lymph nodes 134.2 4.5 29.8
Liver 733.3 35.0 21.0
Spleen 211.3 5.3 39.9
Plasma 77.8 2.3 33.8
Values, expressed in nmol indinavir/g tissue or ml plasma/h, were calculated from the mean values of the tissue distribution pro¢le us-
ing the trapezoidal rule.
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cally stabilized anti-HLA-DR immunoliposomes
were e⁄cient in delivering high concentrations of
the antiretroviral agent to all tissues and in plasma
for at least 15 days post-injection (panel B). On the
other hand, a high concentration of 14C-labeled lip-
ids was observed in the cervical and brachial lymph
nodes at 6 and 24 h post-administration (panel C).
Table 1 shows the corresponding area under the
Fig. 2. In vitro e⁄cacy of free indinavir (a), indinavir incorporated in liposomes (R) or anti-HLA-DR immunoliposomes (b) to in-
hibit HIV-1 replication in PM1 cells. The drug concentration of indinavir in all formulations was 10 nM (A), 25 nM (B), 50 nM (C)
and 100 nM (D). Uninfected cells (E) and untreated infected cells (O) were used as controls. Results represent the average of tripli-
cate incubations from one experiment typical of three.
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curve of free and immunoliposomal indinavir in tis-
sues. The results clearly demonstrate that the incor-
poration of indinavir into sterically stabilized anti-
HLA-DR immunoliposomes greatly enhanced the
drug concentration in all tissues leading to a 21^
126-fold increased accumulation when compared to
the free agent.
3.3. In vitro e⁄cacy experiments
Fig. 2 shows the e⁄cacy of di¡erent concentra-
tions of indinavir, free or encapsulated in liposomes
or anti-HLA-DR immunoliposomes, to inhibit HIV-
1 replication in PM1 cells. Globally, both liposomal
and immunoliposomal formulations of indinavir
Fig. 3. Levels of aspartate aminotransferase (A), alanine aminotransferase (B) and lactate dehydrogenase (C) in serum of mice after
10 daily subcutaneous administrations of 500 Wl of free indinavir, indinavir incorporated in sterically stabilized liposomes and drug-
free sterically stabilized liposomes (34.3 mg indinavir/kg; 540 mg of lipids/kg body weight/day). Levels of hepatic enzymes were moni-
tored in serum samples taken on days 0 (open bars), 11 (dotted bars) and 24 (¢lled bars). Animals treated with a 0.86% DMSO solu-
tion and untreated animals were used as controls. Values represent the means ( þ S.E.M.) obtained from 10 animals per group per
time point.
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were as e⁄cient as the free agent to inhibit HIV-1
replication in this cell line. Infected cells treated with
solutions of DMSO and with empty liposomes at the
same concentration as used for the preparation of
liposomal indinavir had no e¡ect on the inhibition
of viral replication (data not shown). No cellular
toxicity was observed in all groups. Similar results
were obtained when using anti-CD4 immunolipo-
somes on Sup-T1 cells (data not shown).
3.4. In vivo toxicity studies
The toxicity of free and liposomal indinavir was
also evaluated after 10 consecutive subcutaneous in-
jections to mice from histopathology studies and
measurements of hepatic enzymes. No signi¢cant dif-
ferences in the levels of hepatic enzymes of mice
treated with free or liposomal indinavir were ob-
served at the end of the treatment (day 11) and after
Fig. 4. Levels of antibodies in serum samples of rats after repeated subcutaneous injections of liposomes, immunoliposomes or a mix-
ture of liposomes and antibodies on (A) Y-17 IgG-coated plates and (B) Y-17 FabP fragment-coated plates. Values represent the
means ( þ S.E.M.) obtained from ¢ve animals per group per time point.
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the 2 week recovery (day 24) when compared to
baseline and control untreated mice (Fig. 3). Histo-
pathological studies revealed no signi¢cant damage
to liver and spleen when compared to the control
group (data not shown).
3.5. Immunogenicity of immunoliposomes
Fig. 4 shows the levels of antibodies in serum sam-
ples of rats after four repeated subcutaneous injec-
tions of di¡erent preparations of liposomes, immu-
noliposomes or a mixture of liposomes and
antibodies. No important levels of antibodies were
detected at baseline and 6 days after the ¢rst injec-
tion (data not shown). However, the concentration
of antibodies in serum increased rapidly with the
number of injections. As expected, liposomes bearing
FabP fragments were 2.3-fold less immunogenic than
liposomes bearing the entire IgG. Lower levels of rat
antibodies were detected on FabP fragment-coated
plates, suggesting that the immune response is prin-
cipally directed against the Fc portion of immuno-
globulin. In order to verify the speci¢city of these
antibodies, ELISA was performed with irrelevant
protein BSA and no signal was detected (data not
shown).
4. Discussion
Active antiretroviral therapy has been shown to be
e¡ective to reduce the plasma viral load to undetect-
able levels in HIV-infected individuals and to mark-
edly diminish the number of HIV-1 RNA copies in
secondary lymphoid tissues [10,11,37]. However, the
capacity of HIV-1 to establish latent infection of
CD4 T cells allows viral particles to persist in tis-
sues despite immune responses and antiretroviral
therapy. Recent studies have shown that anti-HIV
regimens do not fully eliminate viral replication in
secondary lymphoid tissues and this continued repli-
cation of HIV-1 seems to be associated with the pres-
ence of drug-sensitive viruses [16]. Previous observa-
tions have demonstrated that HIV accumulates and
replicates actively in lymph nodes as soon as 7 days
after primary infection [1,5,38]. Moreover, viral par-
ticles bound onto the FDC remained highly infec-
tious for CD4 T cells despite the presence of neu-
tralizing antibodies on their surface [39,40].
Consequently, the development of alternative ap-
proaches that target lymphoid tissues, the main res-
ervoir for HIV, remains a high priority to treat more
e⁄ciently this infection.
As the HLA-DR determinant is abundantly ex-
pressed on antigen-presenting cells such as mono-
cyte/macrophages and FDC, attachment of anti-
HLA-DR antibodies to sterically stabilized lipo-
somes represents an attractive strategy to concentrate
drugs within HIV reservoirs. On the other hand,
since protease inhibitors are known to have a poor
oral bioavailability because of digestion or binding to
gut proteases and rapid metabolism, their incorpora-
tion into immunoliposomes should improve their ac-
cumulation within HIV reservoirs. The results ob-
tained in the present study clearly demonstrate that
sterically stabilized anti-HLA-DR immunoliposomes
are very e⁄cient in delivering high concentrations of
indinavir to lymphoid tissues increasing by up to 126
times the drug accumulation in lymph nodes. This
enhanced drug accumulation is associated with the
high speci¢city of the anti-HLA-DR FabP fragments
for HLA-DR-expressing cells since the presence of
an irrelevant isotype-matching FabP fragment on
sterically stabilized liposomes had no e¡ect on the
tissue distribution pro¢le of liposomes being similar
to that of non-targeted sterically stabilized liposomes
[34]. A greater drug concentration was observed in
the cervical and brachial lymph nodes when com-
pared to other tissues. These data are in agreement
with our previous observations showing that steri-
cally stabilized immunoliposomes mostly accumulate
in lymph nodes near the injection site [34]. High lev-
els of immunoliposomal drug were also observed in
the liver which is most likely due to the small diam-
eter of immunoliposomes (100^120 nm) which allows
them to extravasate from lymphatic vessels to reach
the blood circulation and be taken up by macro-
phages of liver [28]. Despite this important drug ac-
cumulation in liver, signi¢cant levels of indinavir
were delivered to lymphoid organs for at least 15
days post-injection.
The toxicity of repeated administrations of lipo-
somal formulations has also been investigated in
mice. Even though indinavir is given to patients as
oral tablets, in the present study, we used the same
dose level but given subcutaneously because of the
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instability of liposomal formulations in the chemi-
cally harsh environment encountered in the gastro-
intestinal tract (low pH, action of degradative en-
zymes and bile salts). Moreover, subcutaneous
injection of liposomal drugs constitutes the ideal
route of administration to target lymphoid tissues
as previously demonstrated in the literature. Histo-
pathology studies and measurements of hepatic en-
zymes showed no signi¢cant toxicity to liver and
spleen following repeated subcutaneous administra-
tions of free and liposomal indinavir. Such site-spe-
ci¢c drug targeting may allow less frequent adminis-
trations of antiviral agents and at lower doses than
conventional therapy, thus reducing the marked tox-
icity currently seen in patients undergoing antiviral
therapy with free drugs.
In this study, we have demonstrated that anti-
HLA-DR immunoliposomes containing indinavir
were as e⁄cient as the free agent to inhibit HIV-1
replication in PM1 cells which express high levels of
cell surface HLA-DR. However, because immunoli-
posomes allow e⁄cient drug targeting of HIV reser-
voirs, the potential therapeutic advantages of immu-
noliposomes over the free agent for the treatment of
HIV infection might be expected to be observed
under in vivo situations. We have also observed
that the incorporation of indinavir into non-targeted
liposomes was as e⁄cient as the immunoliposomal
drug to inhibit viral replication in this cell line.
This could be explained by the fact that an in vitro
system is static, allowing a part of non-targeted lipo-
somes to unspeci¢cally bind to cells [41].
In recent years, it has been well demonstrated that
resting, latently infected CD4 T lymphocytes con-
stitute a life-long reservoir for HIV [13,18,42]. Once
activated, these cells provide a new source for HIV-1
propagation. Consequently, it is important to target
these cells in order to prevent primary infection and
establishment of latency. We therefore evaluated the
e⁄cacy of indinavir encapsulated in anti-CD4 immu-
noliposomes to inhibit HIV-1 replication in Sup-T1
cells, a CD4-expressing cell line. Once again, the re-
sults showed that the immunoliposomal drug was as
e⁄cient as free indinavir to inhibit viral replication.
These results suggest that a targeted drug delivery
system could possibly minimize infection of resting
CD4 T cells and inhibit viral replication upon their
reactivation, thereby limiting the expansion of virus.
Harding et al. [43] have demonstrated that the
immunogenicity of PEG-coated liposomes bearing
complete antibodies following three subcutaneous in-
jections in mice was almost exclusively associated
with the Fc portion of the immunoglobulin. In the
present study, we have used anti-HLA-DR FabP
fragments rather than the entire antibody to reduce
immunogenicity associated with the Fc portion. In
order to con¢rm this hypothesis, we have evaluated
the levels of antibodies produced in rat sera follow-
ing four weekly subcutaneous injections of liposomes
bearing complete or FabP fragments of murine anti-
bodies using IgG and FabP-coated ELISA plates. We
have also used two groups injected with a mixture of
liposomes and uncoupled IgG or FabP fragments to
evaluate if the coupling of the antibody to liposomes
enhanced the immune response. Results showed that
liposomes bearing FabP fragments were 2.3-fold less
immunogenic than immunoliposomes^IgG after four
injections. The coupling of proteins to liposomes did
not a¡ect the di¡erence observed between IgG and
FabP fragments. A lower level of rat antibodies re-
acted on plates coated with FabP fragments indicat-
ing that the major part of the response was directed
against the Fc portion. As the immune response ma-
tures, antibodies directed against all parts of the pro-
tein were most likely produced explaining the in-
creased levels of rat antibodies detected against
liposomes bearing FabP fragments. Moreover, one
should keep in mind that FabP fragments still harbor
a part of the Fc portion, which could possibly be
responsible for the immunological stimulation.
Although not well understood, the immune response
of animals immunized with sterically stabilized lipo-
somes alone may be associated with the presence of
natural non-speci¢c antibodies in rat serum directed
against murine epitopes present on murine IgG
coated on plates. This is supported by previous stud-
ies showing that natural antibodies reacting with
liposomes are found in serum of non-immunized
rats [44]. Since these antibodies appear at a later
time point and are produced at much lower levels
than others, one could think that their speci¢cities
are low, thus reacting with sequences present on
murine immunoglobulin. Liposomes bearing Fv frag-
ments, which constitute the smallest part of the im-
munoglobulin that keeps a⁄nity for ligand, could
possibly reduce induction of immune response asso-
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ciated with repeated administrations of immunolipo-
somes.
With a chronic disease such as HIV infection we
need approaches that could improve the treatment of
HIV-infected individuals. A key factor to reduce vi-
ral burden in HIV reservoirs resides in the use of a
more selective drug delivery system. Immunolipo-
somes targeted to speci¢c epitopes such as HLA-
DR or CD4 receptors could represent a strategic
approach to deliver higher levels of drugs within cells
susceptible to infection, thereby increasing their e⁄-
cacy against HIV-1. Such targeted delivery system
should hopefully o¡er new alternatives to the ther-
apy of this deadly disease.
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